selective estrogen receptor modulator


Also found in: Dictionary, Acronyms, Encyclopedia, Wikipedia.
Related to selective estrogen receptor modulator: tamoxifen

modulator

 [mod´u-la″ter]
a specific inductor or agent that brings out characteristics peculiar to a definite region.
selective estrogen receptor modulator (SERM) an agent that activates some estrogen receptors but not others, thereby having estrogenlike effects on target tissues (such as bone) without affecting other tissues that have estrogen receptors.

selective estrogen receptor modulator (SERM),

pharmaceutical agent with selective estrogen receptor affinity; current preparations have a primary effect on bone and cardiovascular tissues and less effect on endometrial, genital, and breast tissues.

selective estrogen receptor modulator

n.
Abbr. SERM Any of a group of nonsteroidal drugs, such as raloxifene and tamoxifen, that bind to estrogen receptors and act in some cases as estrogen agonists and in others as estrogen antagonists.

selective estrogen receptor modulator (SERM)

an agent that activates some estrogen receptors but not others, thereby having estrogen-like effects on target tissues without affecting other tissues that have estrogen receptors.

selective estrogen receptor modulator

Designer estrogen, SERM Therapeutics A drug–eg, idoxifene, raloxifene–Evista®, which, like estrogen, prevents bone loss and ↓ cholesterol but, unlike estrogen, does not stimulate the endometrium and breast and thus does not ↑ risk of breast and endometrial CA. See Estrogen receptor, Raloxifene.

se·lec·tive es·tro·gen re·cep·tor mod·u·la·tor

(SERM) (sĕ-lek'tiv es'trŏ-jen rĕ-sep'tŏr mod'yū-lā'tŏr)
Pharmaceutical agent with selective estrogen receptor affinity; current preparations have a primary effect on bone and cardiovascular tissues and less effect on endometrial, genital, and breast tissues.

Selective estrogen receptor modulator

A hormonal preparation that offers the beneficial effects of hormone replacement therapy without the increased risk of breast and uterine cancer associated with HRT.
Mentioned in: Osteoporosis
References in periodicals archive ?
RAD1901 is a novel selective estrogen receptor modulator (SERM) under development at Radius as a new class of menopausal therapy.
Wyeth describes the pairing of a selective estrogen receptor modulator (SERM) and one or more estrogens as a TSEC.
But interest in the drug, which is a beuzothiophene-derivative selective estrogen receptor modulator, was revived after reports that long-term tamoxifen use was associated with endometrial cancer, Dr.
GTx has completed a pivotal Phase III clinical trial evaluating toremifene citrate, a selective estrogen receptor modulator, or SERM, at an 80 mg dose for the prevention of bone fractures and treatment of other estrogen deficiency side effects of androgen deprivation therapy in men with prostate cancer.
The study is the second pivotal Phase 3 clinical trial for Ophena(TM), a new selective estrogen receptor modulator (SERM) for the treatment of postmenopausal vaginal syndrome (PVS), a common condition in postmenopausal women.
April: Wyeth received approval from the European Commission (EC) for CONBRIZA[TM] (bazedoxifene), a selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in post-menopausal women at increased risk of fracture.
Ophena(TM), a novel selective estrogen receptor modulator (SERM), is being studied as a non-estrogen alternative for the treatment of symptoms of postmenopausal vaginal syndrome (PVS), also known as vaginal atrophy.
Toremifene 80 mg is an oral selective estrogen receptor modulator which GTx seeks to market for the prevention of bone fractures in men with prostate cancer on androgen deprivation therapy (ADT).
Nasdaq: GTXI) announced today that the United States Food and Drug Administration has accepted for filing and review the New Drug Application (NDA) for toremifene 80 mg, an oral selective estrogen receptor modulator, which GTx seeks to market for the prevention of bone fractures in men with prostate cancer on androgen deprivation therapy (ADT).
Lasofoxifene is a selective estrogen receptor modulator, or SERM, in the same chemical class as raloxifene.
Ophena(TM) is a novel selective estrogen receptor modulator (SERM) that is being studied as a treatment for women with postmenopausal vaginal syndrome (PVS), also known as vaginal atrophy.

Full browser ?